Suyoung Bae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Suyoung Bae has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Hyunjhung Jhun
Research Group of Nutraceuticals for Metabolic Syndrome, Korea Food Research Institute, Seongnam, Korea
1 shared publication - Jaewoo Hong
Department of Physiology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea
1 shared publication - Taewon Han
Infrastructure Support Team, Korea Food Research Institute, Wanju-gun 55365, Republic of Korea
1 shared publication - Yasmin Hisham
Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 12 June 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (2) , 3
IL-32γ plays a neuroprotective role after acute stroke in MCAO mouse model
Stroke is believed to be the most common cause of permanent disability and is regarded as the second major cause of death. Within minutes of onset, cerebral ischemia triggers a cascade of pathophysiological events that ultimately result in irreversible tissue damage. Post-ischemic inflammation plays a critical role in cerebral ischemia-reperfusion injury, characterized by the elevated release of cytokines and chemokines. Interleukin (IL)-32 is known to induce several cytokines, particularly pro-inflammatory ones such as IL-6, tumor necrosis factor (TNF)α, and IL-1β. Targeting inflammatory pathways are of great interest in stroke research. In this study, we investigated the role of IL-32γ in a middle cerebral artery occlusion (MCAO) model using transgenic (TG) mice expressing human IL-32γ. Compared to wild-type (WT) mice, IL-32γ TG mice exhibited a significantly reduced infarct volume after MCAO. Accompanying the decreased brain tissue damage, the levels of pro-inflammatory cytokines IL-6, TNFα, and IL-1β were markedly lower in IL-32γ TG mice than in WT controls. These findings suggest that IL-32γ modulates the inflammatory response in ischemic brain injury. Specifically, IL-32γ reduced the expression of pro-inflammatory cytokines and the number of apoptotic cells following ischemic insult. In conclusion, our results demonstrate that IL-32γ regulates the neuroinflammatory response in brain injury and may serve as a potential neuroprotective therapeutic target.
- 12 June 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (2) , 3
Open AccessIL-32γ plays a neuroprotective role after acute stroke in MCAO mouse model
Stroke is believed to be the most common cause of permanent disability and is regarded as the second major cause of death. Within minutes of onset, cerebral ischemia triggers a cascade of pathophysiological events that ultimately result in irreversible tissue damage. Post-ischemic inflammation plays a critical role in cerebral ischemia-reperfusion injury, characterized by the elevated release of cytokines and chemokines. Interleukin (IL)-32 is known to induce several cytokines, particularly pro-inflammatory ones such as IL-6, tumor necrosis factor (TNF)α, and IL-1β. Targeting inflammatory pathways are of great interest in stroke research. In this study, we investigated the role of IL-32γ in a middle cerebral artery occlusion (MCAO) model using transgenic (TG) mice expressing human IL-32γ. Compared to wild-type (WT) mice, IL-32γ TG mice exhibited a significantly reduced infarct volume after MCAO. Accompanying the decreased brain tissue damage, the levels of pro-inflammatory cytokines IL-6, TNFα, and IL-1β were markedly lower in IL-32γ TG mice than in WT controls. These findings suggest that IL-32γ modulates the inflammatory response in ischemic brain injury. Specifically, IL-32γ reduced the expression of pro-inflammatory cytokines and the number of apoptotic cells following ischemic insult. In conclusion, our results demonstrate that IL-32γ regulates the neuroinflammatory response in brain injury and may serve as a potential neuroprotective therapeutic target.